No generic version of Rexulti is currently available in the United States. The drug is still under patent protection [1].
When does the Rexulti patent expire?
The patents protecting Rexulti are set to expire in 2037 [1]. This means that a generic version of Rexulti cannot be legally marketed until after these patents have expired.
Can biosimilars enter before patent expiry?
Biosimilars are typically approved for biologic drugs, while Rexulti (brexpiprazole) is a small molecule drug. Therefore, the concept of biosimilars does not apply to Rexulti. Instead, generic versions of small molecule drugs are developed and approved [2].
What is Rexulti used for?
Rexulti is a prescription medication used to treat schizophrenia in adults and as an add-on treatment for major depressive disorder in adults [3]. It works by affecting the activity of certain neurotransmitters in the brain, such as dopamine and serotonin [4].
What companies are involved with Rexulti?
Rexulti was developed by Otsuka Pharmaceutical and is marketed by Otsuka and Lundbeck [5].
Where can I find more information on drug patents?
DrugPatentWatch.com provides comprehensive data on drug patents, including expiration dates and patent challenges for various medications [1].
---
Sources
[1] DrugPatentWatch.com
[2] FDA.gov
[3] Rexulti.com
[4] RxList.com
[5] Otsuka.com